ArticlePreventive medicine2025
Factors associated with human papillomavirus (HPV) patient-clinician communication and HPV vaccine uptake among adults in the United States.
Article in Preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Occupational HPV exposure and vaccination among healthcare workers: Implications for institutional vaccination strategies.Human vaccines & immunotherapeutics · 2026Article
- Article
- Article
- Examining Artificial Intelligence Chatbots' Responses in Providing Human Papillomavirus Vaccine Information for Young Adults: Qualitative Content Analysis.JMIR public health and surveillance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveHuman papillomavirus (HPV) vaccine is approved for those aged 9-45 years. However, HPV vaccine uptake remains suboptimal in the United States (U.S.), particularly among young and mid-age adults. This paper describes HPV vaccine patient-clinician communication, clinician recommendation receipt, and HPV vaccine uptake among U.S. adults who were eligible for the HPV vaccine as adults.
methodsU.S. adults up to age 45 and who were aged 18+ when the HPV vaccine was approved were recruited for an online survey (n = 1107) between February-March 2021. Multivariable logistic regression analyses were used to assess: (1) clinician-patient HPV vaccination discussions; (2) ever having received an HPV vaccine recommendation from a clinician; and (3) HPV vaccine uptake.
resultsThirty-four percent of participants reported having prior HPV vaccine discussions with a clinician, 31.1 % reporting ever having received a clinician recommendation for the vaccine, and only 23.8 % reported receiving the vaccine. Receiving the HPV vaccine was positively associated with prior HPV vaccine discussions (aOR: 2.93; 95 % CI: 1.98-4.35) and ever receiving an HPV vaccine recommendation from a clinician (aOR: 10.64; 95 % CI: 7.14-15.88). Additional factors consistently associated with all three models (discussing, receiving a clinician recommendation, and vaccine uptake) include higher HPV vaccine knowledge and higher HPV vaccine embarrassment.
conclusionsUnvaccinated age-eligible adults represent a missed opportunity for HPV-related cancer prevention. Interventions to support clinicians providing care to young and mid-age adults are needed to increase clinician discussions and recommendations of the HPV vaccine and patient uptake of the HPV vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.